Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based studyResearch in context

• Váldodahkkit: Yoko Narasaki (Dahkki), Csaba P. Kovesdy (Dahkki), Amy S. You (Dahkki), Keiichi Sumida (Dahkki), Yamini Mallisetty (Dahkki), Satya Surbhi (Dahkki), Fridtjof Thomas (Dahkki), Alpesh N. Amin (Dahkki), Elani Streja (Dahkki), Kamyar Kalantar-Zadeh (Dahkki), Connie M. Rhee (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2024-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Summary: Background: We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [GLP1a]) in patients with and without chronic kidne...